A Phase 2, Open-Label, Multicenter Study of the GARFT Inhibitor in Patients With Metastatic Non-Small Cell Lung Cancer
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine safety and activity of a novel anticancer
agent in patients with metastatic non-small cell lung cancer who failed 2 or 3 prior systemic
treatments.